Precigen (PGEN) Long-Term Debt Issuances (2013 - 2025)

Precigen (PGEN) reported Long-Term Debt Issuances of -$654000.0 for Q4 2025, down 273.94% quarter-over-quarter from $376000.0 in Q1 2019.

Precigen (PGEN) Long-Term Debt Issuances (2013 - 2025) Analysis & Trends

Precigen (PGEN) has 8 years of Long-Term Debt Issuances data on file, last reported at -$654000.0 in Q4 2025.

Long-Term Debt Issuances for Q4 2025 came in at -$654000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was -$654000.0 (changed N/A YoY), and the FY2025 annual result was $92.8 million, changed N/A from the prior year.
Long-Term Debt Issuances retreated to -$654000.0 in Q4 2025 per PGEN's latest filing, from $376000.0 in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at -$654000.0 in Q4 2025 and troughed at -$654000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	LT Debt Issuance (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-	2.73 Mn
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn	-
9	Abivax	94.37 Bn	94.37 Bn	-	-
10	Precigen	1.27 Bn	1.27 Bn	20.69 Mn	-

Download Data